Atlas Trials

Sutro Biopharma, Inc.

7 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Sutro Biopharma, Inc.

RecordFirmDate
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer (NCT07227168)Sutro Biopharma, Inc.2025-11-07
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML (NCT06679582)Sutro Biopharma, Inc.2024-12-04
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer (NCT06555263)Sutro Biopharma, Inc.2024-08-21
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (NCT05870748)Sutro Biopharma, Inc.2023-07-12
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (NCT05200364)Sutro Biopharma, Inc.2022-03-22
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers (NCT03748186)Sutro Biopharma, Inc.2019-02-01
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (NCT03424603)Sutro Biopharma, Inc.2018-02-22

Track Sutro Biopharma, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.